Recro Pharma

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for the treatment of pain, initially in the post-operative setting. Our lead product, an intranasal formulation of Dexmedetomidine, or Dex, has completed a Phase Ib placebo controlled trial demonstrating pain relief. We have studied various dosage forms of Dex in eight completed clinical studies, two of which were placebo controlled trials that demonstrated meaningful pain relief. As our product candidates are not opioid based drugs, we expect to overcome many of the side effects associated with commonly prescribed opioid based therapeutics, including addiction, constipation and respiratory distress while maintaining analgesic, or pain relieving, effect. We are ready to begin a Phase IIb trial with Dex in patients experiencing post-operative pain. We believe Dex will become an alternative pain medication to opioids for the more than 50 million surgical procedures that require post-operative pain medication. If approved, Dex would also be the first and only approved post-operative pain drug in its class of drugs.
Type
Public
HQ
Malvern, US
Size (employees)
186 (est)
Recro Pharma is headquartered in Malvern, US

Recro Pharma Office Locations

Recro Pharma has an office in Malvern
Malvern, US (HQ)
490 Lapp Rd

Recro Pharma Data and Metrics

Recro Pharma Financial Metrics

Recro Pharma's revenue was reported to be $69.3 m in FY, 2016 which is a 33% increase from the previous period.
Numbers are in $, USD

Revenue (FY, 2016)

69.3 m

Revenue growth (FY, 2015 - FY, 2016), %

33%

Gross profit (FY, 2016)

32.2 m

Gross profit margin (FY, 2016), %

46%

Net income (FY, 2016)

(30.2 m)

EBIT (FY, 2016)

(25.8 m)

Market capitalization (22-Jun-2017)

131.1 m

Closing share price (22-Jun-2017)

6.7

Cash (31-Dec-2016)

64.5 m

EV

91 m
Recro Pharma's current market capitalization is $131.1 m.
FY, 2014FY, 2015FY, 2016

Revenue

52 m69.3 m

Revenue growth, %

33%

Cost of goods sold

28.1 m37.2 m

Gross profit

23.9 m32.2 m

Gross profit Margin, %

46%46%

R&D expense

7.9 m12.3 m33.3 m

General and administrative expense

4 m13 m12.7 m

Operating expense total

11.9 m58.9 m95.1 m

EBIT

(11.9 m)(7 m)(25.8 m)

EBIT margin, %

(13%)(37%)

Interest expense

(4.3 m)(5.6 m)(5.6 m)

Interest income

10.5 k12 k49 k

Pre tax profit

(16.1 m)(12.5 m)(31.3 m)

Income tax expense

15.6 m1.1 m

Net Income

(16.1 m)3 m(30.2 m)
FY, 2014FY, 2015FY, 2016

Cash

19.7 m19.8 m64.5 m

Accounts Receivable

89.6 k8.6 m10.4 m

Inventories

9 m1.1 m

Current Assets

20.4 m38.7 m84.8 m

PP&E

37.9 m37.3 m

Goodwill

6.4 m6.4 m

Total Assets

20.4 m138.7 m183 m

Accounts Payable

869.9 k1.6 m4.1 m

Total Debt

11.9 m29.8 m24.4 m

Current Liabilities

1.4 m9.5 m16.3 m

Common Stock

77.1 k92 k190 k

Additional Paid-in Capital

52.9 m71.3 m132.7 m

Retained Earnings

(34.1 m)(31.1 m)(61.3 m)

Total Equity

18.9 m40.4 m71.6 m

Debt to Equity Ratio

0.6 x0.7 x0.3 x

Debt to Assets Ratio

0.6 x0.2 x0.1 x

Financial Leverage

1.1 x3.4 x2.6 x
FY, 2014FY, 2015FY, 2016

Net Income

(16.1 m)3 m(30.2 m)

Depreciation and Amortization

1.4 k4.1 m5 m

Accounts Receivable

(51.2 k)4 m(1.8 m)

Inventories

1.3 m(325 k)

Accounts Payable

1.1 m2.2 m8.5 m

Cash From Operating Activities

(10.9 m)8.5 m(3.2 m)

Purchases of PP&E

(2.4 m)(3.8 m)

Cash From Investing Activities

(55.1 m)(3.8 m)

Long-term Borrowings

(16.3 m)(6.3 m)

Cash From Financing Activities

30.5 m46.7 m51.7 m

Interest Paid

4.9 m4.5 m
Numbers are in $, USDY, 2016

EV/EBIT

-3.5 x

EV/CFO

-28.4 x

Revenue/Employee

372.8 k

Debt/Equity

0.3 x

Debt/Assets

0.1 x

Financial Leverage

2.6 x

Recro Pharma Operating Metrics

FY, 2016

Patents Issued

13

Patents Granted

49

Recro Pharma Market Value History

Recro Pharma Revenue Breakdown

Recro Pharma News and Updates

Recro Pharma Company Life and Culture

You may also be interested in